| Nombre | MARIA GUADALUPE ISABEL DOMINGUEZ GOMEZ |
|---|---|
| Área | MEDICINA Y CIENCIAS DE LA SALUD |
| Campo | INVESTIGACIÓN MÉDICA |
| Disciplina | OTRAS ESPECIALIDADES MÉDICAS |
| Especialidad | ONCOLOGIA, QUIMIOTERAPIA, CIRUGIA ONCOLOGIA |
| CVU | 204526 |
| Institución | |
|---|---|
| Dependencia | DIVISION DE INVESTIGACION BASICA |
| Entidad | CIUDAD DE MEXICO |
| Nivel | 1 |
| Vigencia | Inicio: 01/01/2024 |
| Fin: 31/12/2028 |
Publicaciones ORCID
- 2021
- Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy Scientific Reports
- 2020
- Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug Cancer Chemotherapy and Pharmacology
- Investigation of HER-2 status, treatment response and survival analysis in cervical cancer patients European Journal of Gynaecological Oncology
- The combination of orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells Oncology Letters
- 2019
- A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells Oncology Letters
- Growth inhibition and transcriptional effects of ribavirin in lymphoma Oncology Reports
- 2018
- Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in ras-transformed NIH 3T3 cells OncoTargets and Therapy
- Ivermectin as an inhibitor of cancer stem-like cells Molecular Medicine Reports
- Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy Expert Opinion on Investigational Drugs
- 2017
- Feasibility and antitumor efficacy in vivo, of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer Oncology Letters
